NEW YORK (GenomeWeb) – The Gene Editing Institute of the Helen F. Graham Cancer Center has signed an agreement to provide gene editing services and genetically modified cell lines to Analytical Biological Services (ABS), the partners announced today.
Under the terms of the three-year deal, the Gene Editing Institute will be the sole provider of gene editing services and genetically modified cell lines to ABS for replication, marketing, and distribution to pharmaceutical and biomedical research companies worldwide.
Additional terms were not disclosed.
"This partnership greatly enhances our capability to provide the highest quality genetically engineered cells for drug discovery," ABS President and CEO Charles Saller said in a statement.
"ABS has the know-how to grow and expand the cells in sufficient quantities, as well as to market them to pharmaceutical and biotechnology clients for drug screening and research," Gene Editing Institute Founder and Director Eric Kmiec added.